Abstract
In populations with mixed vaccination status, testing programs focused on the unvaccinated have been proposed and enacted to mitigate the spread of SARS-CoV-2. While the benefits of universal SARS-CoV-2 screening are well established, it is unclear how the benefits of unvaccinated-only testing depend on population vaccination rate. Here, we introduce and analyze a model of SARS-CoV-2 transmission in which a variable fraction of the population is fully vaccinated and those who remain unvaccinated are proactively tested for infection, while varying transmission rates, vaccine performance parameters, and the degree of social mixing between vaccinated and unvaccinated populations. We find that unvaccinated testing programs are effective only when compliance is high and testing is frequent, and when vaccine coverage is low or moderate. However, in highly vaccinated populations, the impact of testing unvaccinated individuals decreases, and, by analyzing the possible modes of transmission within and between the unvaccinated and vaccinated populations, we show that the unvaccinated community ceases to be the dominant driver of transmission. By evaluating a wide range of scenarios, this work focuses on elucidating general principles, finding broadly that resources devoted to routine testing of the unvaccinated population could be reallocated to other needs when vaccine coverage is sufficiently high.
Competing Interest Statement
R.P. is a founder of Faze Therapeutics. D.B.L. is an advisor to Darwin BioSciences and has received consulting fees from iCareDx. All other authors declare no conflicts of interest.
Funding Statement
K.M.B. and C.E.M. were supported in part by the Interdisciplinary Quantitative Biology (IQ Biology) Ph.D. program at the BioFrontiers Institute, University of Colorado Boulder. C.E.M and D.B.L. were supported in part by the SeroNet program of the National Cancer Institute (1U01CA261277-01). R.P. was supported by the Howard Hughes Medical Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All code is open source and provided by the authors.
